Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 9, 119
eCollection

Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic

Affiliations
Review

Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic

Amie L Severino et al. Front Psychiatry.

Abstract

Prescription opioid misuse is an ongoing and escalating epidemic. Although these pharmacological agents are highly effective analgesics prescribed for different types of pain, opioids also induce euphoria, leading to increasing diversion and misuse. Opioid use and related mortalities have developed in spite of initial claims that OxyContin, one of the first opioids prescribed in the USA, was not addictive in the presence of pain. These claims allayed the fears of clinicians and contributed to an increase in the number of prescriptions, quantity of drugs manufactured, and the unforeseen diversion of these drugs for non-medical uses. Understanding the history of opioid drug development, the widespread marketing campaign for opioids, the immense financial incentive behind the treatment of pain, and vulnerable socioeconomic and physical demographics for opioid misuse give perspective on the current epidemic as an American-born problem that has expanded to global significance. In light of the current worldwide opioid epidemic, it is imperative that novel opioids are developed to treat pain without inducing the euphoria that fosters physical dependence and addiction. We describe insights from preclinical findings on the properties of opioid drugs that offer insights into improving abuse-deterrent formulations. One finding is that the ability of some agonists to activate one pathway over another, or agonist bias, can predict whether several novel opioid compounds bear promise in treating pain without causing reward among other off-target effects. In addition, we outline how the pharmacokinetic profile of each opioid contributes to their potential for misuse and discuss the emergence of mixed agonists as a promising pipeline of opioid-based analgesics. These insights from preclinical findings can be used to more effectively identify opioids that treat pain without causing physical dependence and subsequent opioid abuse.

Keywords: biased agonism; chronic pain; mixed agonists; opioid epidemic; opioid use disorder; oxycodone; pharmacokinetics.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. Defalque RJ, Wright AJ. Scophedal (SEE) was it a fad or a miracle drug? Bull Anesth Hist (2003) 21:12–4.10.1016/S1522-8649(03)50051-8 - DOI - PubMed
    1. Rappaport B. Overview of the November 13, 2008 ALSDAC Meeting to Discuss NDA 22-324 for Remoxy (Oxycodone Hydrochloride Controlled-Release) Capsules A. Division of Anesthesia, and Rheumatology Products, Office of Drug Evaluation II, editor. , editor (2008).
    1. Aquina CT, Marques-Baptista A, Bridgeman P, Merlin MA. OxyContin abuse and overdose. Postgrad Med (2009) 121(2):163–7.10.3810/pgm.2009.03.1988 - DOI - PubMed
    1. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health (2009) 99(2):221–7.10.2105/AJPH.2007.131714 - DOI - PMC - PubMed
    1. Ventola CL. Direct-to-consumer pharmaceutical advertising: therapeutic or toxic? P T (2011) 36:669–84. - PMC - PubMed

LinkOut - more resources

Feedback